Understanding side effects before you start is one of the most important things you can do for your treatment. Patients who know what to expect, and how to manage it, are far less likely to stop a medication that could genuinely transform their health. The majority of Mounjaro side effects are gastrointestinal, temporary, and closely tied to dose increases.
The most common side effects
In the UK product information, nausea, diarrhoea, vomiting, constipation and stomach pain are listed as very common in the weight-management trials, affecting more than 1 in 10 people, and indigestion and injection-site reactions as common, affecting up to 1 in 10. Nausea affected 24.6% to 29.0% of people on tirzepatide, depending on the dose, compared with 8.5% on placebo. Individual results vary.
| Side effect | Frequency | Typically worst during |
|---|---|---|
| Nausea | Very common (>1 in 10; 24.6% to 29.0% depending on dose, compared with 8.5% on placebo) | First 4 to 8 weeks and after each dose increase |
| Diarrhoea | Very common | First 4 weeks and after dose increases |
| Constipation | Very common | Can persist; worsens with dehydration |
| Vomiting | Very common | First 4 to 8 weeks |
| Indigestion | Common | Particularly after fatty or rich foods |
| Abdominal pain | Very common | First 8 weeks |
| Injection site reactions | Common (8.0%, compared with 1.8% on placebo) | At injection site |
How common are Mounjaro side effects?
In the weight-management trials (SURMOUNT-1 and SURMOUNT-2), nausea affected 25%, 29% and 28% of people on 5mg, 10mg and 15mg, compared with 8% on placebo; diarrhoea 19%, 21% and 23%, compared with 8%; vomiting 8%, 11% and 13%, compared with 2%; constipation 17%, 14% and 11%, compared with 5%; stomach pain 9%, 9% and 10%, compared with 5%; indigestion 9%, 9% and 10%, compared with 4%; and injection-site reactions 6%, 8% and 8%, compared with 2%. Individual results vary. Most side effects are temporary and improve with time.
Why nausea happens, and why it improves
Nausea is caused by the slowing of gastric emptying. Food stays in the stomach longer than your body is accustomed to, generating a sensation similar to overeating. For most patients, the gut adapts within 4 to 8 weeks at each dose level. Nausea is typically worst in the first week at a new dose and improves progressively from there.
How to minimise GI side effects
- Eat smaller portions: Mounjaro slows gastric emptying significantly. Smaller, more frequent meals are far better tolerated than large ones.
- Avoid fatty, greasy, and processed foods: high-fat foods slow emptying further. Lean protein, vegetables, and complex carbohydrates are much better tolerated.
- Eat slowly: aim for 20 to 30 minutes per main meal, chewing thoroughly.
- Stay well hydrated: 2 to 2.5 litres of fluid daily. Dehydration worsens nausea and is a serious risk during episodes of vomiting or diarrhoea.
- Try injecting in the evening: peak nausea occurs 24 to 72 hours post-injection and may coincide with sleep for some patients. This is not universal but worth trying.
- Do not rush titration: the 4-week period at each dose exists precisely to allow your body to adjust. There is no clinical benefit to escalating faster, and a significant quality-of-life cost.
Constipation
Constipation is very common. In the two main weight-management trials (SURMOUNT-1 and SURMOUNT-2), it affected 17% of people on 5mg, 14% on 10mg and 11% on 15mg, compared with 5% on placebo. Individual results vary. It tends to be more persistent than nausea and is caused by significantly slowed gut motility. The most important intervention is staying well hydrated, followed by regular physical activity and a fibre-rich diet. If constipation persists, over-the-counter osmotic laxatives are safe to use alongside Mounjaro, discuss this with your pharmacist.
Hair loss
Temporary hair shedding typically begins 2 to 4 months after starting treatment and lasts 3 to 6 months. The UK product information lists hair loss as a common side effect of Mounjaro, and much of the shedding seen during rapid weight loss is telogen effluvium, a stress response to the weight loss. Hair growth returns to normal once weight stabilises for the vast majority of patients. Adequate protein intake (at least 1.2g per kilogram of body weight daily) and ensuring no deficiencies in iron or zinc appear to reduce the severity.
Serious side effects
Pancreatitis: presents as severe upper abdominal pain radiating to the back, accompanied by nausea and vomiting. Pancreatitis is uncommon (up to 1 in 100 people). Stop Mounjaro immediately and seek urgent medical attention. If pancreatitis is confirmed, Mounjaro must not be restarted. It has not been studied in people who have had pancreatitis before, and we do not supply it if you have.
Gallbladder disease: right-sided upper abdominal pain after eating, especially fatty meals. Rapid weight loss is associated with gallstone formation. Gallstones are common in people taking Mounjaro for weight loss (up to 1 in 10 people).
Acute kidney injury: a risk if prolonged vomiting or diarrhoea leads to dehydration. Seek medical attention if symptoms are severe or persistent.
Diabetic retinopathy: patients with pre-existing retinopathy should have their eyes monitored during treatment.
Injection site reactions
Injection-site reactions, such as redness or itching, are common. In the weight-management trials in the UK product information, they affected 8.0% of people on tirzepatide compared with 1.8% on placebo, and almost all were mild. Individual results vary. Rotate injection sites weekly, choosing a different area within your thigh or abdomen each time. The back of your upper arm can also be used if someone else gives the injection.
"Starting at 2.5mg and increasing slowly is the single most effective way to minimise side effects. Most patients find symptoms improve significantly within 4 to 8 weeks at each dose level."